Marrone Bio Innovations Inc
NASDAQ:MBII
Intrinsic Value
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of MBII.
Marrone Bio Innovations Inc's market capitalization is 145.8m USD.
MBII stock price is 0.8 USD.
MBII.
MBII. Open DCF Valuation
MBII. Open Relative Valuation
MBII.
MBII's Revenue has grown by 12% over the past 12 months.
MBII's ROIC (Return on Invested Capital) has decreased in the last 3 years from -23% to -27%, and is approaching profitability.
MBII's long-term assets (76m USD) exceed its long-term liabilties (53m USD).
MBII has negative Net Debt. This means that the company has more cash and short-term investments (9m USD) than debt (8m USD).
MBII's short-term liabilties (42m USD) exceed its short-term assets (33m USD).
MBII's ROE (Return on Equity) has significantly decreased in the last 3 years from -54% to -72%, and is approaching profitability.
MBII has negative Operating Income for the last twelve months.
MBII has negative Net Income for the last twelve months.
MBII's ROE (Return on Equity) for the past 12 months is negative and is equal to -72%.
MBII's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -27%.
MBII has positive Gross Profit for the last twelve months.
MBII's D/E (Debt to Equity) is very low and is equal to 0.33.
MBII has negative Free Cash Flow for the last twelve months.
MBII has negative three-year average ROE (Return on Equity): -130%. The company is not efficient at transforming stockholders' equity into net income.
MBII has negative three-year average ROIC (Return on Invested Capital): -40%. The company is not efficient at using invested capital to generate operating income.
MBII's Altman Z-Score is very low and is equal to -4.95.
MBII doesn't generate enough operating income (-17m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
Marrone Bio Innovations Inc
Balance Sheet Decomposition
Marrone Bio Innovations Inc
| Current Assets | 33m |
| Cash & Short-Term Investments | 9.4m |
| Receivables | 12.1m |
| Other Current Assets | 11.5m |
| Non-Current Assets | 43.3m |
| PP&E | 15.8m |
| Intangibles | 18.4m |
| Other Non-Current Assets | 9m |
| Current Liabilities | 41.7m |
| Accounts Payable | 3.4m |
| Accrued Liabilities | 13.8m |
| Other Current Liabilities | 24.6m |
| Non-Current Liabilities | 11.6m |
| Long-Term Debt | 7.6m |
| Other Non-Current Liabilities | 4m |
Earnings Waterfall
Marrone Bio Innovations Inc
|
Revenue
|
44.4m
USD
|
|
Cost of Revenue
|
-17.9m
USD
|
|
Gross Profit
|
26.5m
USD
|
|
Operating Expenses
|
-43.9m
USD
|
|
Operating Income
|
-17.4m
USD
|
|
Other Expenses
|
-3.5m
USD
|
|
Net Income
|
-20.9m
USD
|
Free Cash Flow Analysis
Marrone Bio Innovations Inc
MBII Profitability Score
Profitability Due Diligence
Marrone Bio Innovations Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Marrone Bio Innovations Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
MBII Solvency Score
Solvency Due Diligence
Marrone Bio Innovations Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Marrone Bio Innovations Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MBII Price Targets Summary
Marrone Bio Innovations Inc
Ownership
MBII Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MBII Price
Marrone Bio Innovations Inc
| Average Annual Return | -5.09% |
| Standard Deviation of Annual Returns | 44.63% |
| Max Drawdown | -79% |
| Market Capitalization | 145.8m USD |
| Shares Outstanding | 182 261 000 |
| Percentage of Shares Shorted | 2.18% |
Company Profile
Marrone Bio Innovations Inc
Country
Industry
Market Cap
Dividend Yield
Description
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. The company is headquartered in Raleigh, North Carolina and currently employs 153 full-time employees. The company went IPO on 2013-08-02. The Company’s products include Emergen, Foramin, Foramin ST, Grandevo, Haven, Jet-Ag, Jet-Oxide, Majestene, Pacesetter, Regalia, Stargus, UBP, UBP ST, Venerate and Zelto. Its product categories include products, which are referred to as biopesticides, bioinsecticides, bionematicides, biofungicides, biostimulants and bionutrition. Its pipeline consists of products in three categories: bioprotection, seed and soil health, and plant health. The Company’s markets include row crops, such as corn and soybeans; fruits and vegetables, such as tomatoes, leafy greens and cucurbits, trees; nuts and vines, such as almonds and grapes, and greenhouse production, such as ornamentals and medicinal plants.
You don't have any saved screeners yet
